Ym Wahyono Tri, Mahkota Renti, Nurcandra Fajaria, Ansariadi Ansariadi, Hidajah Atik C, Helda Helda, Syahrul Fariani, Dwinata Indra, Kawi Nurhayati
Department of Epidemiology, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.
Doctor of Public Health Program in Epidemiology, Faculty of Public Health, Mahidol University, Bangkok, Thailand.
Narra J. 2025 Apr;5(1):e1957. doi: 10.52225/narra.v5i1.1957. Epub 2025 Mar 24.
At the onset of the coronavirus disease 2019 (COVID-19) pandemic in Indonesia, surveillance focused on finding and treating symptomatic cases. However, emerging evidence indicated that asymptomatic and pre-symptomatic individuals significantly contributed to viral transmission. This highlights the need for comprehensive surveillance to understand better the actual spread of SARS-CoV-2. Therefore, the aim of this study was to determine the seroprevalence of SARS-CoV-2 antibodies in the general population across Indonesia and identify risk factors associated with infection at the beginning of the pandemic. A cross-sectional survey was conducted across 17 provinces, 69 districts/cities, and 1,020 villages in Indonesia from December 22, 2020, to February 15, 2021. A multistage random sampling technique was employed. Serological testing using enzyme-linked immunosorbent assay (ELISA) was performed to detect anti-SARS-CoV-2. Complex sample analysis, adjusted for weights, was utilized to estimate the national seroprevalence and a generalized linear model with a binomial distribution was applied to identify risk factors. A total of 10,161 individuals were included in the final analysis, with the national seroprevalence being 14.8% (95% confidence interval (CI): 14.2-18.5). The prevalence was higher in females (16.8%; 95%CI: 12.5-22.3), individuals aged 46-59 years (18.6%; 95%CI: 14.2-24.0), and in urban areas (20.1%; 95%CI: 15.0-26.2). The highest prevalence was observed in North Maluku (35.6%; 95%CI: 29.3-42.5). Notably, 54.2% of seropositive individuals were asymptomatic, while 7.5% reported hypertension as a comorbidity. Factors associated with higher seroprevalence were being married (adjusted prevalence ratio (aPR): 1.47; 95%CI: 1.02-2.12), widow (aPR: 1.74; 95%CI: 1.01-3.00), and close contact with confirmed cases (aPR: 2.04; 95%CI: 1.52-2.73). This study revealed a COVID-19 prevalence significantly higher than official estimate in Indonesia, underscoring the need for improved surveillance system to more accurately track disease spread and to inform timely public health responses in the future.
在印度尼西亚2019冠状病毒病(COVID-19)大流行初期,监测重点是发现和治疗有症状的病例。然而,新出现的证据表明,无症状和症状前个体对病毒传播有显著贡献。这凸显了进行全面监测以更好地了解严重急性呼吸综合征冠状病毒2(SARS-CoV-2)实际传播情况的必要性。因此,本研究的目的是确定印度尼西亚普通人群中SARS-CoV-2抗体的血清阳性率,并确定大流行开始时与感染相关的风险因素。2020年12月22日至2021年2月15日,在印度尼西亚的17个省、69个区/市和1020个村庄进行了一项横断面调查。采用了多阶段随机抽样技术。使用酶联免疫吸附测定(ELISA)进行血清学检测以检测抗SARS-CoV-2抗体。采用经权重调整的复杂样本分析来估计全国血清阳性率,并应用具有二项分布的广义线性模型来确定风险因素。最终分析共纳入10161人,全国血清阳性率为14.8%(95%置信区间(CI):14.2 - 18.5)。女性(16.8%;95%CI:12.5 - 22.3)、46 - 59岁个体(18.6%;95%CI:14.2 - 24.0)以及城市地区(20.1%;95%CI:15.0 - 26.2)的血清阳性率较高。北马鲁古的血清阳性率最高(35.6%;95%CI:29.3 - 42.5)。值得注意的是,54.2%的血清阳性个体无症状,而7.5%报告有高血压作为合并症。与较高血清阳性率相关的因素包括已婚(调整后患病率比(aPR):1.47;95%CI:1.02 - 2.12)、丧偶(aPR:1.74;95%CI:1.01 - 3.00)以及与确诊病例密切接触(aPR:2.04;95%CI:1.52 - 2.73)。本研究显示,印度尼西亚的COVID-19患病率显著高于官方估计,强调需要改进监测系统,以便更准确地追踪疾病传播,并为未来及时的公共卫生应对提供信息。